Rubius Therapeutics, Inc. (NASDAQ:RUBY) Sees Large Increase in Short Interest
Rubius Therapeutics, Inc. (NASDAQ:RUBY) Sees Large Increase in Short Interest
Rubius Therapeutics, Inc. (NASDAQ:RUBY – Get Rating) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 2,800,000 shares, an increase of 83.0% from the February 13th total of 1,530,000 shares. Currently, 6.1% of the company's stock are short sold. Based on an average trading volume of 4,100,000 shares, the days-to-cover ratio is currently 0.7 days.
Rubius 治療公司（NASDAQ：紅寶石-獲取評級）是二月份短期興趣顯著增加的收件人。截至 2 月 28 日，短期利息共達 2,800,000 股，較 2 月 13 日的總股 1,530,000 股增加 83.0%。目前，該公司股票的 6.1％ 賣空。根據 4,100,000 股的平均交易量計算，目前的日數比率為 0.7 天。
Institutional Investors Weigh In On Rubius Therapeutics
機構投資者權衡在 Rubius 治療
Several institutional investors have recently bought and sold shares of RUBY. Renaissance Technologies LLC grew its holdings in Rubius Therapeutics by 617.0% during the second quarter. Renaissance Technologies LLC now owns 826,458 shares of the company's stock worth $703,000 after buying an additional 711,190 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Rubius Therapeutics in the 3rd quarter valued at $236,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in Rubius Therapeutics by 521.5% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 353,813 shares of the company's stock valued at $301,000 after purchasing an additional 296,886 shares during the period. AQR Capital Management LLC bought a new position in Rubius Therapeutics in the 2nd quarter valued at $140,000. Finally, BlackRock Inc. grew its stake in Rubius Therapeutics by 11.3% in the 3rd quarter. BlackRock Inc. now owns 1,587,927 shares of the company's stock valued at $688,000 after purchasing an additional 161,695 shares during the period. Institutional investors own 76.11% of the company's stock.
一些機構投資者最近買賣了 RUBY 的股票。文藝復興技術有限責任公司在第二季度增加了 617.0％ 在 Rubius 治療學的持有量。文藝復興科技有限責任公司現在擁有該公司股票的 826,458 股，價值 703,000 美元，在上一個季度購買了 711,190 股之後。雅各布斯徵收股權管理公司在第三季度買入了 Rubius 治療學的新頭寸，價值為 236,000 美元。康納·克拉克朗投資管理有限公司在第二季度增長了 521.5％ 在 Rubius 治療學的股份。康納克拉克倫投資管理有限公司於期內額外購入 296,886 股股份後，現時擁有該公司 353,813 股價值 301,000 元的股份。AQR 資本管理有限責任公司在第二季度購買了一個新的位置，價值為 14 萬美元。最後，貝萊德公司在第三季度將其在 Rubius 治療的股份增長了 11.3％。在期內額外購買 161,695 股股份後，貝萊德公司現在擁有該公司股票的 1,587,927 股股份，價值 688,000 美元。機構投資者擁有公司股票的 76.11%。
Rubius Therapeutics Trading Down 26.8 %
魔法治療學交易下降 26.8%
Rubius Therapeutics stock traded down $0.01 during trading on Friday, hitting $0.04. 1,397,974 shares of the company were exchanged, compared to its average volume of 9,594,584. The business's 50 day moving average is $0.20 and its 200 day moving average is $0.33. Rubius Therapeutics has a 52 week low of $0.03 and a 52 week high of $6.18.
瑞比斯治療學股市周五交易期間下跌 0.01 美元，觸及 0.04 美元。該公司的 1,397,974 股被交換，而該公司的平均交易量為 9,594,584。該業務的 50 日移動平均線為 0.20 美元，其 200 日移動平均線為 0.33 美元。魔法治療學具有 52 周低點 0.03 美元，52 周高點為 6.18 美元。
About Rubius Therapeutics
關於魔法治療
(Get Rating)
(取得評分)
Rubius Therapeutics, Inc engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Foxboro, MA.
Rubius Theraptics, Inc 從事癌症，自身免疫性疾病，血友病以及傳染性和代謝性疾病的紅細胞治療藥物的開發。該公司由阿瓦克·卡韋堅，喬迪·馬塔-芬克和努巴爾阿菲揚於 2013 年 4 月 26 日成立，總部設在馬薩諸塞州福克斯波羅。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Rubius Therapeutics (RUBY)
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- 獲取有關魔法治療（紅寶石）的研究報告
- 市場節拍週的回顧 — 3/6 — 3/10
- 2 海上鑽探股票將提取巨額利潤
- 前面有兩位數字的三個主要股票
- 投資者可以信任消費者提升美國戶外品牌嗎？
- 如何購買高收益股息股票
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收《魔方治療》的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Rubius 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。